

MOL #8847

Pharmacological differences between human and guinea pig histamine H₁ receptors: Asn⁸⁴ (2.61) as key residue within an additional binding pocket in the H₁ receptor.

Martijn Bruysters, Aldo Jongejan, Michel Gillard, Frank van de Manakker, Remko A. Bakker, Pierre Chatelain and Rob Leurs

Leiden/Amsterdam Center for Drug Research, Faculty of Sciences, Department of Medicinal Chemistry, Vrije Universiteit Amsterdam, The Netherlands (M.B., A.J., F. vd. M., R.A.B., and R.L.).

UCB S.A. Pharma Sector, Braine-l'Alleud, Belgium (M.G. and P.C.).

MOL #8847

a) Running title: Species selectivity of histamine H₁ receptors.

b) Corresponding author:

Prof. Dr. R. Leurs

Leiden / Amsterdam Center for Drug Research, Faculty of Sciences,
Department of Medicinal Chemistry, Vrije Universiteit Amsterdam.

De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands.

Tel: ++31 20 5987579

Fax: ++31 20 5987610

E-mail: r.leurs@few.vu.nl

| | | |
|----|--|------|
| c) | Number of text pages: | 30 |
| | Number of tables: | 2 |
| | Number of figures: | 5 |
| | Number of references: | 35 |
| | Number of words in Abstract: | 176 |
| | Number of words in Introduction: | 790 |
| | Number of words in Results and discussion: | 2321 |

d) List of non-standard abbreviations

| | |
|------------------|--------------------------------------|
| TM | transmembrane domain |
| H ₁ R | histamine H ₁ receptor |
| GPCRs | G-protein coupled receptors |
| COS-7 | African green monkey kidney cells |
| TF | 2-(3-trifluoromethylphenyl)histamine |
| MeHP | N ^α -Methylhistaprodifen |
| HP-HA | Histaprodifen-histamine dimer |
| HP-HP | Histaprodifen-histaprodifen dimer |

MOL #8847

Abstract

We tested several histamine H₁ receptor (H₁R) agonists and antagonists for their differences in binding affinities between human and guinea pig H₁Rs transiently expressed in African green monkey kidney (COS-7) cells. Especially the bivalent agonist histaprodifen-histamine (HP-HA) shows a higher affinity for guinea pig than for human H₁Rs. Based on the structure of HP-HA, we have further identified VUF 4669 as a guinea pig-preferring H₁R antagonist, demonstrating that the concept of species-selectivity is not limited to agonists. To delineate the molecular mechanisms behind the observed species-selectivity we have created mutant human H₁Rs in which amino acids were individually replaced by their guinea pig H₁R counterparts. Residue Asn⁸⁴ (2.61) in transmembrane domain 2 (TM2) appeared to act as a selectivity switch in the H₁R. Molecular modeling and site-directed mutagenesis studies suggests that Asn⁸⁴ interacts with the conserved Tyr⁴⁵⁸ (7.43) in TM7. Our data provide the first evidence that for some H₁R ligands, the binding pocket is not limited to TMs 3, 4, 5 and 6, but also comprises an additional pocket formed by TMs 2 and 7.

MOL #8847

The biogenic amine histamine exerts its effects through binding and activation of four G protein-coupled receptors (GPCRs), the H₁, H₂, H₃ and H₄ receptors. The H₁ receptor (H₁R) regulates inflammatory and allergic responses and is successfully targeted by various drugs. H₁R antagonists have been on the market since 1942 for the treatment of allergies and newer, non-sedating second-generation H₁R antagonists are still the medication of choice to relief certain allergic symptoms (Hill et al., 1997).

In contrast to the development of various potent H₁R antagonists, the synthesis of selective and potent H₁R agonists has not achieved the same success (Hill et al., 1997). Only in 1995 2-(3-trifluoromethylphenyl)histamine (TF) was discovered as the first selective H₁R agonist with a potency equal to histamine as determined by the H₁R-mediated guinea pig ileum contractions (Leschke et al., 1995; Zingel et al., 1995). Recently, Elz et al. (2000) synthesized a series of compounds constituting a new class of highly active H₁R agonists, the histaprodifens. Histaprodifen combines a histamine moiety linked at the 2-position with an ω,ω -diphenylalkyl substituent, a characteristic of the H₁R antagonist pharmacophore (ter Laak et al., 1995; Zhang et al., 1997). Based on this new H₁R agonist, "dimeric" histaprodifens were subsequently developed, consisting of a histaprodifen moiety linked at the N ^{α} position to e.g. another histamine moiety (HP-HA) (Menghin et al., 2003). Compared to histamine, the potency of HP-HA is reported to be 36- to 56-fold and 630-fold higher on guinea-pig isolated ileum and trachea, respectively (Christophe et al., 2003; Seifert et al., 2003).

MOL #8847

Contrary to the potencies at either the guinea pig ileum and trachea or rat aorta (Christophe et al., 2003; Elz et al., 2000; Seifert et al., 2003), the potencies of various histaprodifen analogues (histaprodifen, MeHP, HP-HA and HP-HP) at human H₁Rs are at best similar to the potency of the endogenous ligand histamine (Bruysters et al., 2004; Seifert et al., 2003), indicating a potential species difference at the level of the H₁R recognition of these H₁R agonists.

In aminergic GPCRs, including the H₁R, the ligand-binding pocket is thought to reside in a hydrophilic cleft formed by the 7 transmembrane domains (TMs). Within the third TM (TM3) an aspartate (Asp) residue is a conserved feature among these aminergic GPCRs and is likely to make a direct contact with the protonated amine of aminergic ligands (Shi and Javitch, 2002). Indeed, in the human H₁R Asp¹⁰⁷ in TM3 (residue 3.32 according to the Ballesteros-Weinstein numbering) is part of the binding pocket of both H₁R agonists and antagonists (Bruysters et al., 2004; Moguilevsky et al., 1998; Nonaka et al., 1998; Ohta et al., 1994). Several additional amino acids in TM5 and TM6 are part of the H₁R binding pocket of histamine: Lys¹⁹¹ (5.39) (Bruysters et al., 2004; Gillard et al., 2002; Leurs et al., 1995; Moguilevsky et al., 1998; Wieland et al., 1999), Asn¹⁹⁸ (5.46) (Bruysters et al., 2004; Leurs et al., 1994; Moguilevsky et al., 1995; Ohta et al., 1994) and Phe⁴³⁵ (6.55) (Bruysters et al., 2004) are considered to accommodate the imidazole ring of histamine. The H₁R antagonist binding pocket stretches deeper into the receptor protein and comprises the aromatic amino acids Trp¹⁵⁸ (4.56) (Wieland et al., 1999) and Phe⁴³² (6.52) (Bruysters et al., 2004; Wieland et al., 1999).

MOL #8847

Recently, we studied the binding pocket of several histaprodifen analogues in the human H₁R (Bruysters et al., 2004). We demonstrated that histamine and the histamine moiety of histaprodifens bind to the human H₁R in a similar orientation. While the diphenylalkyl-system of histaprodifen interacts with the H₁R in an “antagonistic binding mode“, *i.e.* interacting with Phe⁴³² (6.52) in TM6 (Bruysters et al., 2004), no interactions with Lys¹⁹¹ (5.39) and Phe⁴³⁵ (6.55) were found. Again, the interaction with both Asp¹⁰⁷ (3.32) proved crucial. Although Asn¹⁹⁸ (5.46) did not affect histaprodifen affinity, it appeared pivotal for agonist-induced activation of the hH₁R. An interaction between Asn¹⁹⁸ (5.46) and histaprodifen was therefore suggested (Bruysters et al., 2004).

We explored in this study the molecular basis of the observed species differences between human and guinea pig H₁R by a combined approach of molecular modeling and site-directed mutagenesis. We reevaluated several H₁R agonists and antagonists for their differences in affinity between human and guinea pig H₁R by [³H]mepyramine displacement studies. Based on our knowledge of the H₁R binding site of the histaprodifens and the high (93%) level of sequence homology within the TM domains of the human and guinea pig H₁R, we extended our approach to mutant human H₁R in which selected amino acids were individually replaced by their guinea pig H₁R counterparts. Using this strategy, we identified Asn⁸⁴ (2.61) in TM2 as the molecular basis for the observed species selectivity of certain H₁R ligands and discuss the implications of these findings for future drug design.

MOL #8847

Materials and methods

Chemicals

Chloroquine diphosphate, DEAE-dextran (chloride form), histamine dihydrochloride, mepyramine (pyrilamine maleate), astemizole, ketotifen fumarate, 8*R*-lisuride and terfenadine were purchased from Sigma Aldrich (Bornem, Belgium). Oxatomide was obtained from ICN Biomedicals, Inc. (Zoetermeer, The Netherlands). Fexofenadine was purchased from Ultrafine Chemicals (Manchester, UK). VUF 4669 7-(3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propoxy)-4-oxochroman-2-carboxylic acid and VUF 8401 (3-(1*H*-imidazol-4-yl)propyl)-3-(2-(benzhydrylthio)ethyl)guanidine dipicrate were synthesized at the Vrije Universiteit Amsterdam, The Netherlands. Cetirizine dihydrochloride (Zyrtec[®]) and loratidine were synthesized at UCB SA, Braine l'Alleud, Belgium.

Gifts of 2-(3-trifluoromethylphenyl)HA dihydrogenmaleate, histaprodifen (2-[2-(3,3-diphenylpropyl)imidazol-4-yl]ethanamine dihydrogenmaleate), methylhistaprodifen (*N*^α-methyl-histaprodifen dihydrogenoxalate), histaprodifen-histaprodifen dimer trihydrogenoxalate and histaprodifen-histamine dimer (*N*^α-[2-(1*H*-imidazol-4-yl)-ethyl]-histaprodifen trihydrogenoxalate) (Dr. Dr. W. Schunack), the cDNA encoding the human H₁R (Dr. H. Fukui), and the expression vector pcDEF₃ (Goldman et al., 1996) (Dr. J. Langer) are greatly acknowledged.

Cell culture media, penicillin, and streptomycin bovine serum (FBS) were purchased from BioWhittaker (Verviers, Belgium). Cell culture plastics were

MOL #8847

obtained from Greiner Bio-one (Wemmel, Belgium). [³H]mepyramine (~20 Ci/mmol) from Amersham Biosciences (Roosendaal, The Netherlands).

Numbering scheme of GPCRs

The indexing method introduced by Ballesteros and Weinstein (Ballesteros and Weinstein, 1995) was used throughout to identify amino acids in the TM regions. Each residue is identified by two numbers: the first number corresponds to the helix (1 through 7) in which the residue is located, the second number indicates its position relative to the most conserved amino acid in that helix, arbitrarily assigned to 50. Numbers depicted in superscript correspond to the number of the amino acid in the human H₁R.

Site-directed mutagenesis

The cDNA encoding the human H₁R (Fukui et al., 1994) was subcloned in the pAlter plasmid (Promega), and point mutations were created according to manufacturer's protocol (Altered Sites[®] II, Promega). cDNAs of mutant and wild-type receptors were sub-cloned into the expression plasmid pcDEF₃ (Goldman et al., 1996). Sequences were verified by DNA sequencing using the dideoxy chain termination method.

Cell culture, transfection and membrane preparation

COS-7 African green monkey kidney cells were maintained at 37 °C in a humidified 5% CO₂/95% air atmosphere in Dulbecco's Modified Eagle's Medium containing 50 IU/ml penicillin, 50 µg/ml streptomycin and 10% (V/V) FBS. COS-7 cells were transiently transfected using the DEAE-dextran

MOL #8847

method as previously described (Bakker et al., 2001), using 5 μ g plasmid DNA per million cells. Two days post-transfection, cells were detached by scraping, and were harvested by centrifugation. Cell pellets were resuspended in ice-cold water, lysed by repetitive freezing/thawing and frozen in liquid nitrogen. Thus obtained crude cell homogenates were stored at -80°C until further use.

H₁R binding studies

The COS-7 cell homogenates ($\sim 5 \mu\text{g}$) were incubated for 60 min at 30°C in 500 μl binding buffer (50 mM Na₂/K-phosphate buffer (pH = 7.4)) containing 3 nM [³H]mepyramine. The non-specific binding was determined in the presence of 10 μM cetirizine. The incubations were stopped by rapid dilution with ice-cold binding buffer. The bound radioactivity was separated by filtration through Whatman GF/C filters (Whatman, VEL, Belgium) that had been treated with 0.1% polyethylenimine. Filters were washed four times with binding buffer and radioactivity retained on the filters was measured by liquid scintillation counting.

Molecular modeling

Our H₁R homology model was obtained using the bovine rhodopsin crystal structure (Protein Data Bank entry 1L9H, Okada et al., 2002) as the template. Side chains were added using the SCWRL program (Canutescu et al., 2003). Water molecules present in the rhodopsin structure were retained and their heavy atoms were kept fixed during all minimizations and molecular dynamic runs. The position of TM3 was manually changed with regard to the rhodopsin

MOL #8847

structure to avoid a clash between the top of TM3 and TM2 (Lopez-Rodriguez et al., 2002). Due to the presence of the H₁R-specific Trp¹⁵⁸ (4.56), TM3 could not be put into the position as found by molecular modeling studies on the 5HT_{1A} receptor. Therefore, we assumed an intermediate position between the location in the crystal structure of rhodopsin and the proposed location in the 5HT_{1A} receptor model. Short minimizations runs were performed (5000 iterations using steepest descent) to refine the initial model. All minimizations were carried out while fixing the C_α atoms to their initial positions.

Ligands were docked in the wild-type receptor using the automated docking procedure GOLD v2.1 (Jones et al., 1997) applying default parameters. The complex of the Asn⁸⁴Ser mutant receptor with the ligand was obtained by changing the appropriate residue in the WT receptor-ligand model to its guinea pig homologue. The obtained ligand-receptor complexes were used as input structures for further minimization and molecular dynamic studies. First, the position of the ligand is optimized by fixing the receptor except for the residues involved in ligand binding. Gradually, restraints were released before final submission of the resulting complex to two simulated annealing runs at 600 K, each followed by cooling to 200 K before final minimization. In the first round of the simulated annealing run (2500 steps initialization, 5000 steps production, 5000 steps cooling), the C_α atoms of the receptor are fixed to their position as is the ligand. In the second round (15000 steps production, 5000 steps cooling) the ligand is released and free to move.

All minimizations and molecular dynamics simulations were performed using Discover (Accelrys Inc. San Diego).

MOL #8847

Analytical methods

Protein concentrations were determined according to Bradford (Bradford, 1976), using bovine serum albumin as a standard. Binding data were evaluated by a non-linear, least squares curve-fitting procedure using GraphPad Prism 4[®] (GraphPad Software, Inc., San Diego, CA). Obtained pK_i , pEC_{50} and K_d values are expressed as mean \pm S.E.M. of at least three independent experiments. Statistical analyses were carried out by non-paired Student's *t*-test. *P* values < 0.05 were considered to indicate a significant difference (^a: $P < 0.05$, ^b: $P < 0.01$, ^c: $P < 0.001$). Despite significance, differences in pK_i values are only considered relevant when the difference is at least 0.3 logunits.

MOL #8847

Results and discussion

Evaluation of species selectivity of H₁R ligands

Using displacement of [³H]mepyramine binding to guinea pig or human H₁Rs transiently expressed in COS-7 cells, we determined the affinity of a series of H₁R antagonists (cetirizine (Zyrtec[®]), ketotifen (Zaditor[®]), loratidine (Claritin[®]), oxatomide (Tinset[®]), fexofenadine (Allegra[®]), astemizole, terfenadine and mepyramine). As shown in Figure 1, none of the tested H₁R antagonists (open symbols) showed any preference, *i.e.* a difference in pK_i exceeding 0.3 log units (dotted lines), for binding to the guinea pig H₁R over the human H₁R, corroborating recent findings by Seifert and coworkers (Seifert et al., 2003). We also determined the binding affinities of several H₁R agonists (closed symbols) for both human and guinea pig H₁Rs. Again, the general rank order of affinities is shared between human and guinea pig H₁Rs, with histamine having the lowest and the recently characterized partial agonist 8*R*-lisuride (Bakker et al., 2004) having the highest H₁R affinity. Considering all tested agonists and antagonists, we observed a linear correlation ($r^2 = 0.96$) between human and guinea pig H₁R affinities over an affinity range of almost six decades. No species differences were observed between the human and the guinea pig H₁R for the affinities of the endogenous ligand histamine or the synthetic agonists histaprodifen, TF and 8*R*-lisuride. In contrast, MeHP exhibits a 3-fold higher affinity for the guinea pig H₁R than for the human H₁R. For the dimeric compounds HP-HP and HP-HA, the guinea pig over human H₁R-selectivity is even greater (4- and 10-fold, respectively). The higher affinities of these compounds for the guinea pig H₁R

MOL #8847

are in good agreement with the higher potencies of these agonists for guinea pig *versus* human H₁Rs as recently demonstrated using a GTPase assay (Seifert et al., 2003).

The species-dependent pharmacology of several of the histaprodifen analogues is also observed in functional assays. Measuring the effects on the contraction of the guinea-pig ileum, HP-HA is up to 50-fold more potent than histamine (Christophe et al., 2003; Seifert et al., 2003), whereas in assays using heterologously expressed hH₁Rs both HP-HA and histamine appear to be equipotent (Bruysters et al., 2004; Seifert et al., 2003).

Generation and evaluation of human H₁R mutants

The ligand-binding pocket of aminergic receptors is generally considered to reside within the TM domains (Shi and Javitch, 2002). Within these TM domains, several amino acids have been identified in the human and guinea pig H₁R that are important for the interaction of ligands with the H₁R: Asp¹⁰⁷ (3.32) in TM3 (Bruysters et al., 2004; Moguilevsky et al., 1998; Nonaka et al., 1998; Ohta et al., 1994), Trp¹⁵⁸ (4.56) in TM4 (Wieland et al., 1999), Lys¹⁹¹ (5.39) and Asn¹⁹⁸ (5.46) in TM5 (Bruysters et al., 2004; Leurs et al., 1995; Leurs et al., 1994; Moguilevsky et al., 1998; Moguilevsky et al., 1995; Ohta et al., 1994), Phe⁴³² (6.52) and Phe⁴³⁵ (6.55) in TM6. None of these amino acids differ between human and guinea pig H₁Rs. Actually, the sequence similarity within these TMs is high (93%), and only 12 amino acids differ between the two proteins (Figure 2A). In the hH₁R, of these 12 amino acids, only Ile³⁷ (1.42) and Cys³⁸ (1.43) in TM1, Asn⁸⁴ (2.61) and Leu⁸⁹ (2.66) in TM2 and Leu⁴⁴⁹ (7.34) and Ile⁴⁵⁹ (7.44) in TM7 are predicted to be located

MOL #8847

either in close proximity to the hydrophilic cleft in the hH₁R, or on the interface of two TMs (Figure 2B). We therefore reasoned that especially these amino acids may be directly involved in ligand binding, and that one of these residues might be responsible for the observed differences in pharmacology between human and guinea pig H₁R. To test this hypothesis, we created the following mutant hH₁R in which the selected amino acids are individually replaced into their guinea pig counterparts: hH₁R Ile³⁷Val, hH₁R Cys³⁸Ser, hH₁R Asn⁸⁴Ser, hH₁R Leu⁸⁹His, hH₁R Leu⁴⁴⁹Val, and hH₁R Ile⁴⁵⁹Leu. Although in our H₁R model Ile⁴³³ (6.53) points towards the plasma membrane, we also included the mutant hH₁R Ile⁴³³Val receptor in our study since Ile⁴³³ is located in between the established hH₁R-ligand interaction points Phe⁴³² (6.52) and Phe⁴³⁵ (6.55). In general, we noticed that, at the selected positions, the amino acids present in the human H₁R are bulkier than their guinea pig H₁R counterparts (Table 1).

Most of the generated mutant H₁R are expressed at comparable levels (B_{max} values of ~10 pmol/mg) and bind [³H]mepyramine with unchanged affinity (K_d values of 0.5-1.7 nM) when compared to wild-type human H₁R (Table 1). However, the mutant receptor hH₁R-Leu⁸⁹His (2.66), with a point mutation in the top of TM2, did not show any [³H]mepyramine binding at concentrations up to 30 nM and may not be properly expressed at the cell membrane. Displacement of [³H]mepyramine binding indicated that all tested mutant H₁R bind the endogenous agonist histamine with unchanged affinity (Table 2). Only for mutant hH₁R Asn⁸⁴Ser (2.61) receptors, which harbor a point mutation in TM2, the affinities for HP-HA are increased (pK_i = 6.8) compared to the wild-type hH₁R (pK_i = 6.1), resulting in a gpH₁R-

MOL #8847

like ($pK_i = 7.1$) pharmacology (Figure 3, Table 2). Also for HP-HP the species difference was reversed by the Asn⁸⁴Ser mutation (Table 2).

HP-HA is an agonist for the hH₁R as measured using a G $\alpha_{q/11}$ -mediated NF- κ B reporter gene assay ($pEC_{50} = 6.4 \pm 0.1$) with a potency comparable to histamine ($pEC_{50} = 6.4 \pm 0.2$) (Bruysters et al., 2004). For both the gpH₁R and mutant hH₁R Asn⁸⁴Ser (2.61) the potency of HP-HA (pEC_{50} values of 7.2 ± 0.1 and 7.9 ± 0.1 , respectively), strongly exceeds that of histamine (pEC_{50} values of 6.0 ± 0.1 and 6.5 ± 0.1 , respectively). These findings confirm that also in a functional assay we observe species-specific H₁R pharmacology, and the mutant hH₁R Asn⁸⁴Ser not only displays a guinea pig H₁R binding profile, but also a guinea pig H₁R functional profile.

These data suggest that residue Asn/Ser⁸⁴ (2.61) is of critical importance for the observed species-dependent agonist pharmacology of the human and guinea pig H₁Rs. Moreover, these data also indicate that for some H₁R agonists TM2 is part of the H₁R ligand binding-pocket. Interestingly, both human and rat H₁Rs have an asparagine at position 2.61. Measuring endothelium-dependent relaxation of rat aortic rings, Menghin and coworkers (Menghin et al., 2003) have shown that MeHP and HP-HA are equipotent, corroborating our previous findings with human H₁Rs expressed in COS-7 cells (Bruysters et al., 2004). However, measuring guinea pig ileum contractions, the potency of HP-HA exceeds that of MeHP 10-fold (Menghin et al., 2003). These observations further strengthen the involvement of Asn/Ser⁸⁴ (2.61) in the species-dependent H₁R pharmacology. Consequently, pharmacological observations with rat H₁Rs will have more predictive power for the action of ligands at human H₁Rs.

MOL #8847

Characterization of a novel, species-selective H₁R antagonist

The H₁R species-selective interactions were originally observed for bulky H₁R agonists (HP-HA, HP-HP). These compounds appear to interact with the “classical” binding pocket (TMs 3, 4, 5, and 6) and Asn/Ser⁸⁴ (2.61), hereby defining an additional binding pocket near TM2. To test whether the additional interactions are restricted to agonists alone, or are also possible for antagonists, we screened an in-house library of H₁R antagonists. From this selection, VUF 4669 was identified as an H₁R antagonist, which differentiates significantly between human and guinea pig H₁Rs. VUF 4669 showed a 17-fold increase in binding affinity for the guinea pig H₁R ($pK_i = 9.0 \pm 0.1$), compared to its affinity for the human H₁R ($pK_i = 7.7 \pm 0.1$) (Table 2). Apparently, the concept of species-selective binding is not restricted to H₁R agonists, but can also be observed for certain H₁R antagonists. Again, VUF 4669 exhibits an increased affinity for the mutant hH₁ Asn⁸⁴Ser receptor ($pK_i = 8.9 \pm 0.1$), confirming the guinea pig-like pharmacological profile of this mutant human H₁R. The other human to guinea pig H₁R mutants used in this study exhibit an affinity for VUF 4669 that is identical to the affinity for the WT human H₁R (Table 2).

Previously, also several arpromidine analogues, which display both H₁R antagonistic and H₂R agonistic properties, were characterized as guinea pig H₁R-preferring compounds (Seifert et al., 2003). Indeed, VUF 8401, a structural analogue of arpromidine displays a 9-fold higher affinity for the guinea pig H₁R than for the human H₁R (Table 2). Also VUF 8401 binds with an increased affinity to the mutant hH₁R Asn⁸⁴Ser (2.61) (Table 2), although

MOL #8847

this mutation did not fully reverse the species difference. None of the other mutant hH₁Rs show an increased affinity for VUF 8401 (Table 2). Interaction with Asn/Ser⁸⁴ (2.61) therefore partially explains the observed species difference. We hypothesize that for arpromidine-like ligands the higher affinity depends on Ser⁸⁴ (2.61) and additional guinea pig H₁R-specific residues. This hypothesis will be the basis of future investigations.

Like HP-HA and VUF 4669, arpromidine analogues are bulky ligands, having aromatic moieties on either side of a protonated moiety and we hypothesize that these features are mandatory for species-selectivity. H₁R antagonists like terfenadine, fexofenadine and oxatomide, however, also show such features, but appear not to be species-selective. Clearly, the simple presence of 2 aromatic domains in a ligand is not the only denominator for species-selectivity.

Rationalization of the role of Asn⁸⁴ (2.61) in the species-selective binding

To rationalize the potential role of the amino acid at position 2.61 (Asn/Ser) in the species-selective binding of HP-HA, we created a homology model for the human H₁R on the basis of the available structural information on bovine rhodopsin (Okada et al., 2002; Palczewski et al., 2000). In the absence of ligand, our H₁R homology model, suggests hydrogen bonding between Asn⁸⁴ (2.61) and Tyr⁴⁵⁸ (7.43), a residue that is conserved between human and guinea pig H₁Rs. Using the automated docking procedure GOLD v2.1 (Jones et al., 1997) we subsequently docked the agonist HP-HA in the receptor model (Figure 4A). In contrast to H₁R antagonists such as cetirizine, the diphenyl moiety of HP-HA is not oriented towards TM6, but predicted to

MOL #8847

point towards TMs 1, 2 and 7, confirming our previous suggestions based on site-directed mutagenesis studies of the histamine binding pocket (Bruysters et al., 2004). Thereafter, we changed Asn⁸⁴ (2.61) into Ser, thus creating a model of the hH₁R Asn⁸⁴Ser receptor containing HP-HA (Asn⁸⁴Ser model). Molecular dynamics simulations were subsequently performed to optimize both HP-HA containing WT and Asn⁸⁴Ser models. During both simulations, hydrogen bonding was maintained between Asn⁸⁴ (2.61) and Tyr⁴⁵⁸ (7.43) in the WT model (3.31 Å, Figure 4B), and between Ser⁸⁴ (2.61) and Tyr⁴⁵⁸ (7.43) in the Asn⁸⁴Ser model (2.80 Å, Figure 4C). However, the orientation of Tyr⁴⁵⁸ differs between both models, probably due to the structural differences between Ser and Asn at position 2.61 (e.g. length and flexibility of the side chain). Since the affinity of HP-HA is higher for the Asn⁸⁴Ser H₁R, the conformation of HP-HA in the Asn⁸⁴Ser model is considered more favorable. In the WT model, Tyr⁴⁵⁸ occupies the space that in the Asn⁸⁴Ser model is occupied by one of the phenyl rings of HP-HA. Our computational studies therefore suggest that Tyr⁴⁵⁸ might sterically hinder the binding of HP-HA in the hH₁R, thereby “forcing” HP-HA to bind deeper within the receptor.

To test the potential involvement of Tyr⁴⁵⁸ (7.43) in the binding of HP-HA to the human H₁R, we mutated Tyr⁴⁵⁸ (7.43) in the human H₁R into an alanine (hH₁R Tyr⁴⁵⁸Ala). Saturation binding analysis using [³H]mepyramine shows that this mutant H₁R is expressed at comparable levels ($B_{\max} = 8.2 \pm 3.5$ pmol/mg protein) and with an unchanged affinity for [³H]mepyramine ($K_d = 3.0 \pm 0.7$) in comparison to the wild-type H₁R. The Tyr⁴⁵⁸Ala mutation did also not affect the affinity for histamine ($pK_i = 4.4 \pm 0.2$) (Figure 5). Since the mutation Tyr⁴⁵⁸Ala would remove potential steric hindrance between HP-HA

MOL #8847

and the hH₁R, we expected an increased affinity of HP-HA. Indeed, mutation of Tyr⁴⁵⁸ into an alanine results in a 5-fold increase in affinity for HP-HA ($pK_i = 6.8 \pm 0.1$) compared to the wild-type H₁R (Figure 5). This affinity is similar to the affinity of HP-HA for both the gpH₁R ($pK_i = 7.1 \pm 0.1$) and the hH₁R Asn⁸⁴Ser ($pK_i = 6.8 \pm 0.1$) (Table 2).

The results of our computational and mutagenesis studies indicate an important role of Asn⁸⁴ (2.61) as selectivity switch. Moreover, our results illustrate the first structural features of an additional binding pocket between TM2 and TM7 in the H₁R. Residues in both TM2 and TM7 have been implicated in ligand binding for only a few other aminergic receptors (for review see Shi and Javitch, 2002). For example, bulky H₂R agonists were suggested to interact with TM7 in the H₂ receptor (Kelley et al., 2001), whereas dopamine D₂/D₄ receptor subtype-selectivity of several classes of antagonists is determined by a hydrophobic microdomain formed by 6 amino acids in TM2, TM3 and TM7 (including position 2.61) (Javitch et al., 1999). Also for adrenergic receptors, the key to β_1/β_2 agonist-selectivity appears to be localized in TMs 2 and 7 (Isogaya et al., 1999). Moreover, amino acids present at position 7.43 (homologous to hH₁R Tyr⁴⁵⁸) are demonstrated to be involved in ligand binding to 5HT_{2A} (Roth et al., 1997) and muscarinic acetylcholine M₃ receptors (Wess et al., 1991). The involvement of TMs 2 and 7 in the H₁R binding pocket of some H₁R ligands is therefore highly likely.

Conclusions

In conclusion, the human and guinea pig H₁R exhibit significantly different affinities for agonists, like HP-HA and HP-HP, as well as for several

MOL #8847

antagonists such as VUF 4669 and VUF 8401. These differences can be explained by the presence of Asn⁸⁴ (2.61) in the hH₁R *versus* Ser⁸⁴ (2.61) in the gpH₁R. Based on molecular dynamics simulations and site-directed mutagenesis data we suggest a possible role for Tyr⁴⁵⁸ (7.43) in the binding of certain H₁R ligands. Our data provide the first evidence that for these H₁R ligands, TM2 and TM7 are also part of the ligand binding-pocket. Exploitation of these additional interaction points within the H₁R ligand binding-pocket in drug development programs may yield a new generation of antihistamines with increased structural diversity compared to the currently known ligands.

MOL #8847

Acknowledgments

We thank F. Aelbrecht, C. v. d. Perren, G. J. Sterk and J. Hulshof for valuable assistance.

MOL #8847

References

- Bakker RA, Schoonus SB, Smit MJ, Timmerman H and Leurs R (2001)
Histamine H₁-receptor activation of nuclear factor- κ B: roles for G $\beta\gamma$ -
and G $\alpha_{q/11}$ -subunits in constitutive and agonist- mediated signaling. *Mol
Pharmacol* **60**:1133-42.
- Bakker RA, Weiner DM, ter Laak T, Beuming T, Zuiderveld OP, Edelbroek M,
Hacksell U, Timmerman H, Brann MR and Leurs R (2004) 8R-lisuride
is a potent stereospecific histamine H₁-receptor partial agonist. *Mol
Pharmacol* **65**:538-49.
- Ballesteros J and Weinstein H (1995) Intergrated methods for the construction
of three-dimensional models of structure-function relations in G protein-
coupled receptors. *Methods Neurosci.* **25**:366-428.
- Bradford MM (1976) A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. *Anal Biochem* **72**:248-54.
- Bruysters M, Pertz HH, Teunissen A, Bakker RA, Gillard M, Chatelain P,
Schunack W, Timmerman H and Leurs R (2004) Mutational analysis of
the histamine H₁-receptor binding pocket of histaprodifens. *Eur J
Pharmacol* **487**:55-63.
- Canutescu AA, Shelenkov AA and Dunbrack RL, Jr. (2003) A graph-theory
algorithm for rapid protein side-chain prediction. *Protein Sci* **12**:2001-
14.
- Christophe B, Carlier B, Schunack W, Chatelain P, Peck MJ and Massingham
R (2003) Histamine H₁-agonist properties of histaprodifen derivatives

MOL #8847

on guinea-pig isolated trachea and ileum. *Inflammation Research* **52**:S51-S52.

Elz S, Kramer K, Pertz HH, Detert H, ter Laak AM, Kuhne R and Schunack W (2000) Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H₁-receptor agonists. *J Med Chem* **43**:1071-84.

Fukui H, Fujimoto K, Mizuguchi H, Sakamoto K, Horio Y, Takai S, Yamada K and Ito S (1994) Molecular cloning of the human histamine H₁ receptor gene. *Biochem Biophys Res Commun* **201**:894-901.

Gillard M, Van Der Perren C, Moguilevsky N, Massingham R and Chatelain P (2002) Binding characteristics of cetirizine and levocetirizine to human H₁ histamine receptors: contribution of Lys¹⁹¹ and Thr¹⁹⁴. *Mol Pharmacol* **61**:391-9.

Goldman LA, Cutrone EC, Kotenko SV, Krause CD and Langer JA (1996) Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression. *Biotechniques* **21**:1013-5.

Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R and Haas HL (1997) International Union of Pharmacology. XIII. Classification of histamine receptors. *Pharmacol Rev* **49**:253-78.

Isogaya M, Sugimoto Y, Tanimura R, Tanaka R, Kikkawa H, Nagao T and Kurose H (1999) Binding pockets of the β_1 - and β_2 -adrenergic receptors for subtype-selective agonists. *Mol Pharmacol* **56**:875-85.

Javitch JA, Ballesteros JA, Chen J, Chiappa V and Simpson MM (1999) Electrostatic and aromatic microdomains within the binding-site crevice

MOL #8847

of the D2 receptor: contributions of the second membrane-spanning segment. *Biochemistry* **38**:7961-8.

Jones G, Willett P, Glen RC, Leach AR and Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. *J Mol Biol* **267**:727-48.

Kelley MT, Burckstummer T, Wenzel-Seifert K, Dove S, Buschauer A and Seifert R (2001) Distinct interaction of human and guinea pig histamine H₂-receptor with guanidine-type agonists. *Mol Pharmacol* **60**:1210-25.

Leschke C, Elz S, Garbarg M and Schunack W (1995) Synthesis and histamine H₁ receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues. *J Med Chem* **38**:1287-94.

Leurs R, Smit MJ, Meeder R, Ter Laak AM and Timmerman H (1995) Lysine²⁰⁰ located in the fifth transmembrane domain of the histamine H₁ receptor interacts with histamine but not with all H₁ agonists. *Biochem Biophys Res Commun* **214**:110-7.

Leurs R, Smit MJ, Tensen CP, Ter Laak AM and Timmerman H (1994) Site-directed mutagenesis of the histamine H₁-receptor reveals a selective interaction of asparagine²⁰⁷ with subclasses of H₁-receptor agonists. *Biochem Biophys Res Commun* **201**:295-301.

Lopez-Rodriguez ML, Vicente B, Deupi X, Barrondo S, Olivella M, Morcillo MJ, Behamu B, Ballesteros JA, Salles J and Pardo L (2002) Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine(1a) receptor ligands to explore the three-dimensional structure of the receptor. *Mol Pharmacol* **62**:15-21.

MOL #8847

- Menghin S, Pertz HH, Kramer K, Seifert R, Schunack W and Elz S (2003) N^α-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H₁-receptor agonists. *J Med Chem* **46**:5458-70.
- Moguilevsky N, Differding E, Gillard M and Bollen A (1998) Rational drug design using mammalian cell lines expressing site-directed mutants of the human H₁ histaminic receptor. *Animal Cell Technology: Basic & Applied Aspects* **9**:65-69.
- Moguilevsky N, Varsalona F, Guillaume JP, Noyer M, Gillard M, Daliers J, Henichart JP and Bollen A (1995) Pharmacological and functional characterisation of the wild-type and site-directed mutants of the human H₁ histamine receptor stably expressed in CHO cells. *J Recept Signal Transduct Res* **15**:91-102.
- Nonaka H, Otaki S, Ohshima E, Kono M, Kase H, Ohta K, Fukui H and Ichimura M (1998) Unique binding pocket for KW-4679 in the histamine H₁ receptor. *Eur J Pharmacol* **345**:111-7.
- Ohta K, Hayashi H, Mizuguchi H, Kagamiyama H, Fujimoto K and Fukui H (1994) Site-directed mutagenesis of the histamine H₁ receptor: roles of aspartic acid¹⁰⁷, asparagine¹⁹⁸ and threonine¹⁹⁴. *Biochem Biophys Res Commun* **203**:1096-101.
- Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM and Shichida Y (2002) Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. *Proc Natl Acad Sci U S A* **99**:5982-7.
- Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M and Miyano

MOL #8847

M (2000) Crystal structure of rhodopsin: A G protein-coupled receptor.
Science **289**:739-45.

Roth BL, Shoham M, Choudhary MS and Khan N (1997) Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine_{2A} receptors. *Mol Pharmacol* **52**:259-66.

Seifert R, Wenzel-Seifert K, Burckstummer T, Pertz HH, Schunack W, Dove S, Buschauer A and Elz S (2003) Multiple Differences in Agonist and Antagonist Pharmacology between Human and Guinea Pig Histamine H₁-Receptor. *J Pharmacol Exp Ther* **305**:1104-15.

Shi L and Javitch JA (2002) The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. *Annu Rev Pharmacol Toxicol* **42**:437-67.

ter Laak AM, Venhorst J, Donne-Op den Kelder GM and Timmerman H (1995) The histamine H₁-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H₁-antagonists and including a known interaction site on the receptor. *J Med Chem* **38**:3351-60.

Wess J, Gdula D and Brann MR (1991) Site-directed mutagenesis of the m₃ muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. *Embo J* **10**:3729-34.

Wieland K, Laak AM, Smit MJ, Kuhne R, Timmerman H and Leurs R (1999) Mutational analysis of the antagonist-binding site of the histamine H₁ receptor. *J Biol Chem* **274**:29994-30000.

MOL #8847

Zhang M-Q, Leurs R and Timmerman H (1997) Histamine H₁-receptor antagonists, in *Burger's Medicinal Chemistry and Drug Discovery* (Wolf ME ed) pp 495-559, CRC Press, Inc. John Wiley & Sons, Inc., Laguna Beach, California.

Zingel V, Leschke C and Schunack W (1995) Developments in histamine H₁-receptor agonists. *Prog Drug Res* **44**:49-85.

MOL #8847

Footnotes

a) Financial support:

Research of the authors is supported in part by UCB Pharma (Belgium)

b) Reprint requests:

Prof. Dr. R. Leurs, Leiden / Amsterdam Center for Drug Research,
Faculty of Sciences, Department of Medicinal Chemistry, Vrije
Universiteit Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The
Netherlands.

Legends for Figures

Figure 1. Binding affinities (pK_i) of a variety of histaminergic agonists (closed symbols) and antagonists (open symbols) for the human and guinea pig H_1 R_s. The pK_i values for both wild-type human and guinea pig H_1 R_s were determined by [³H]mepyramine displacements. pK_i values for HP-HA (**5**) are indicated by lines perpendicular to the x and y-axes. A line with a slope of unity depicts the ideal correlation between the pK_i values for human and guinea pig H_1 R_s; the dashed lines indicate 0.3 logunits deviation from unity. All values are calculated as mean \pm S.E.M. of at least three experiments.

Figure 2. Snake plot (**A**) and top view (**B**) of the human H_1 R showing the topology of the TM helices. Panel A: amino acids that are conserved in both guinea pig and human H_1 R_s are depicted in white. Residues indicated in grey and black differ between human and guinea pig H_1 R_s. The third intracellular loop is largely omitted from this graph (as indicated by 183 a.a.) since sequence homology in this region is very low. The residues in black have been selected (see text) in this study for a mutagenesis approach. Panel B: the conserved Asp¹⁰⁷ (3.32) is shown space-filling for orientation. Side chains of amino acids that are conserved in both guinea pig and human H_1 R_s are not shown in this view. Amino acids of which side chains are depicted differ between human and guinea pig H_1 R_s. Amino acids selected for mutagenesis are shown as balls-and-sticks.

MOL #8847















Figure 3. Displacement of [³H]mepyramine binding to wild-type hH₁Rs (■) and gpH₁Rs (○), and to the mutant receptor hH₁R Asn⁸⁴Ser (●) by histaprodifen (**A**), and the histaprodifen-histamine dimer (HP-HA, **B**). A representative experiment is shown.

Figure 4. Binding models of HP-HA (orange) in the human H₁R. View from the extracellular side (Panel A) of the wild-type hH₁R. Detailed snapshot of view parallel to TM domains of wild-type (Panel B), and mutant hH₁R Asn⁸⁴Ser (Panel C). Amino acids previously known to interact with H₁R ligands are depicted in blue (Asp¹⁰⁷ (3.32), Lys¹⁹¹ (5.39), Asn¹⁹⁸ (5.46), Phe⁴³² (6.52) and Phe⁴³⁵ (6.55)), Asn/Ser⁸⁴ (2.61) and Tyr⁴⁵⁸ (7.43) are depicted in green.

Figure 5. Displacement of [³H]mepyramine binding to wild-type hH₁Rs (■) and gpH₁Rs (○), and to the mutant receptor hH₁R Tyr⁴⁵⁸Ala (●) by histamine (**A**), and histaprodifen-histamine dimer (HP-HA, **B**). A representative experiment is shown.

Affinities of [³H]mepyramine and expression levels of human and guinea pig H₁Rs and several human H₁R mutants.







The values are determined by saturation [³H]mepyramine binding assays. Data were calculated as the mean ± S.E.M. for at least three experiments, each performed in duplicate. ND indicates that the value could not be determined. Positions of mutations are depicted using the Ballesteros and Weinstein index (Ballesteros and Weinstein, 1995).

| | [³ H]mepyramine | | Location and nature of mutations | | |
|--|-----------------------------|-------------------------------|----------------------------------|---|---|
| | K _d (nM) | B _{max} (pmol/mg) | position | a.a. hH ₁ R | a.a. gpH ₁ R |
| hH ₁ R | 1.2 ± 0.3 | 12.1 ± 0.9 | - | - | - |
| gpH ₁ R | 0.5 ± 0.1 | 5.3 ± 0.8 ^b | - | - | - |
| hH ₁ R-Ile ³⁷ Val | 1.7 ± 0.5 | 11.4 ± 1.5 | 1.42 | Ile  | Val  |
| hH ₁ R-Cys ³⁸ Ser | 1.4 ± 0.1 | 17.1 ± 2.1 | 1.43 | Cys  | Ser  |
| hH ₁ R-Asn ⁸⁴ Ser | 1.1 ± 0.3 | 6.5 ± 1.2 ^a | 2.61 | Asn  | Ser  |
| hH ₁ R-Leu ⁸⁹ His | > 30 | ND | 2.66 | Leu  | His  |
| hH ₁ R-Ile ⁴³³ Val | 0.7 ± 0.1 | 9.9 ± 2.8 | 6.53 | Ile  | Val  |
| hH ₁ R-Leu ⁴⁴⁹ Val | 1.4 ± 0.2 | 9.7 ± 2.7 | 7.34 | Leu  | Val  |
| hH ₁ R-Ile ⁴⁵⁹ Leu | 1.0 ± 0.2 | 10.3 ± 1.5 | 7.44 | Ile  | Leu  |

^aP<0.05, ^bP<0.01

TABLE 2

Binding affinities (pK_i) of H_1R agonists for human and guinea pig H_1R s and several human H_1R mutants. The pK_i values are determined by [3H]mepyramine displacements. Data were calculated as the mean \pm S.E.M. of at least three experiments.

| | Cetirizine | Histamine | HP-HA | HP-HP | VUF 4669 | VUF 8401 |
|--|--|---|--|---|--|--|
| |  |  |  |  |  |  |
| hH ₁ R | 7.9 \pm 0.1 | 4.3 \pm 0.2 | 6.1 \pm 0.1 | 6.8 \pm 0.2 | 7.7 \pm 0.1 | 6.0 \pm 0.1 |
| gpH ₁ R | 7.7 \pm 0.1 ^a | 4.4 \pm 0.2 | 7.1 \pm 0.1 ^c | 7.4 \pm 0.1 ^a | 9.0 \pm 0.1 ^c | 6.9 \pm 0.1 ^c |
| hH ₁ R-Ile ³⁷ Val | 7.7 \pm 0.1 | 3.9 \pm 0.2 | 5.9 \pm 0.1 | 6.9 \pm 0.1 | 8.0 \pm 0.1 | 5.9 \pm 0.1 |
| hH ₁ R-Cys ³⁸ Ser | 7.9 \pm 0.1 | 3.9 \pm 0.1 | 6.1 \pm 0.1 | 6.8 \pm 0.1 | 8.0 \pm 0.1 | 6.0 \pm 0.1 |
| hH ₁ R-Asn ⁸⁴ Ser | 7.5 \pm 0.1 ^c | 4.2 \pm 0.1 | 6.8 \pm 0.1 ^c | 7.3 \pm 0.1 ^a | 8.9 \pm 0.1 ^c | 6.4 \pm 0.1 ^a |
| hH ₁ R-Ile ⁴³³ Val | 8.0 \pm 0.1 | 4.5 \pm 0.2 | 6.2 \pm 0.1 | 7.1 \pm 0.1 | 8.0 \pm 0.1 | 6.1 \pm 0.1 |
| hH ₁ R-Leu ⁴⁴⁹ Val | 7.9 \pm 0.1 | 4.0 \pm 0.1 | 6.0 \pm 0.1 | 7.0 \pm 0.1 | 8.1 \pm 0.1 | 6.0 \pm 0.1 |
| hH ₁ R-Ile ⁴⁵⁹ Leu | 8.0 \pm 0.1 | 4.4 \pm 0.1 | 6.0 \pm 0.1 | 7.0 \pm 0.1 | 7.8 \pm 0.2 | 6.0 \pm 0.1 |

^aP<0.05, ^cP<0.01 vs. hH₁R

Figure 1




Figure 3





Figure 4




Figure 5

